| Patients, n
|
25 |
| Paired studies, n
|
31 |
| Age at catheterization, median (range), mo |
10.2 (0.4–22.4) |
| Gender, male/female, n
|
11/14 |
| Gestational age at birth, median (range), wk |
28 (23–41) |
| Disease, n (%) |
|
| BPD (n = 17) |
22 (70) |
| CDH (n = 4) |
5 (16) |
| Pulmonary hypoplasia (n = 4) |
4 (13) |
| Hospitalized at time of cardiac catheterization, n (%) |
21 (68) |
| Mechanical ventilation at study, n (%) |
16 (52) |
| Cardiac shunts present at study, n (%) |
18 (58) |
| Atrial shunt |
16 (52) |
| Ventricular septal defect |
2 (6) |
| Aortopulmonary collateral vessels, n (%) |
14 (45) |
| Coil-treated at time of study |
3 (10) |
| Medications at study, n (%) |
27 (87) |
| Oxygen |
27 (87) |
| Calcium channel blocker |
2 (6) |
| Sildenafil |
3 (10) |
| Bosentan |
2 (6) |
| Nitric oxide |
10 (32) |
| Epoprostenol |
2 (6) |
| Sedation for cardiac catheterization, conscious/general anesthesia, n
|
6/25 |
